Domperidone Use in GERD

Introduction to Domperidone Therapy

The Asia-Pacific consensus guidelines state that prokinetic agents, including domperidone, have an overall modest effect in GERD treatment, and should be reserved for patients with documented motility disturbances who have failed PPI therapy 1
Domperidone becomes clinically relevant when GERD coexists with documented delayed gastric emptying or gastroparesis, as recommended by the EULAR 2025 guidelines for the treatment of symptomatic motility disturbances 2

The American Academy of Pediatrics recommends against the routine use of prokinetic agents, including domperidone, for treating GERD in infants or older children due to insufficient evidence and significant adverse effects 3
In patients with systemic sclerosis and GERD partially responsive to high-dose PPI, adding domperidone showed similar improvement to alginic acid, with 13.2% non-responders on domperidone versus 21.6% on alginic acid 2

The American Gastroenterological Association suggests that baclofen, a GABA agonist, decreases 24-hour acid exposure and reflux episodes, though it is limited by CNS side effects 1
Alginates added to PPI showed significantly greater complete heartburn resolution in NERD patients, as recommended by the American College of Gastroenterology 1
Metoclopramide remains the only FDA-approved medication for gastroparesis, though it carries a black box warning for tardive dyskinesia and should not exceed 12 weeks, according to the FDA 4

The American College of Gastroenterology recommends confirming GERD diagnosis with endoscopy and/or pH monitoring, optimizing PPI therapy, and investigating for motility disorders if PPI-refractory 1
The European Society of Gastrointestinal Motility recommends screening for cardiac contraindications, such as ECG for QTc, electrolytes, and medication review, before initiating domperidone therapy 1

The American College of Gastroenterology recommends starting with a dose of 10 mg three times a day as the initial dose, with the possibility of increasing to 20 mg three to four times a day if necessary, while avoiding exceeding 30 mg/day due to the risk of QTc prolongation and sudden cardiac death 5

The initial dose of 10 mg three times a day minimizes the cardiovascular risk while providing prokinetic and antiemetic effects 5
The maximum dose should not exceed 20 mg three to four times a day, with a total daily dose not surpassing 30 mg/day when possible, due to cardiac safety considerations 5

The European Medicines Agency recommends against the long-term use of prokinetic agents like domperidona, and treatment should not extend beyond 12 weeks due to cumulative cardiac risks 6
If therapy is required beyond 12 weeks, strongly consider alternatives such as 5-HT3 receptor antagonists (ondansetron) or prucalopride 6, 7

There is a significant risk of QTc prolongation and torsades de pointes, especially with doses exceeding 30 mg/day 5
Patients over 60 years old have a higher risk, and domperidone should be avoided in patients with pre-existing QTc prolongation or electrolyte abnormalities (hypokalemia, hypomagnesemia) 5, 6
Regular QTc monitoring via ECG is recommended, especially for prolonged therapy 6

For ERGE with nausea/vomiting, consider 5-HT3 receptor antagonists like ondansetron 4-8 mg two to three times a day, or phenothiazines like proclorperazine 5-10 mg four times a day 5
Metoclopramide can be used at 5-20 mg three to four times a day, but its use should not exceed 12 weeks due to the risk of tardive dyskinesia 5, 7
For severe gastroparesis without QTc prolongation, prucalopride can be considered as a first-line prokinetic agent without cardiac effects 7